消炎利胆治疗对肝胆结石病术后复发的防治效果  

Diminishing inflammation and accelerating choleresis post-operation to cure chronic cholangitis and prevention from stone recurrence

作　　者：雷正明[1] 黎靖[1] 李秋[1] 张孟瑜[1] 曾道炳[1] 

机构地区：[1]泸州医学院附属医院肝胆外科,四川泸州646000

出　　处：《中国现代医学杂志》2006年第3期423-425,共3页China Journal of Modern Medicine

摘　　要：目的探讨消炎利胆治疗对肝胆结石病术后复发胆管炎的防治作用。方法历史对照比较消炎利胆组(1996年1月￣2004年6月间手术324例,术后消炎利胆治疗1￣3月,并定期驱蛔)、常规治疗组(1986年1月￣1995年12月手术859例)两组术后随访资料。结果消炎利胆组获随访236例,术后胆管炎复发率15.25%(36/236),再手术率5.08%(12/236),常规治疗组获随访537例,胆管炎复发率32.8%(176/537)再手术率16.8%(90/537)。结论肝胆结石病术后中药消炎利胆治疗,定期驱蛔预防胆道蛔虫对防止结石、胆管炎复发有积极作用;术后继续治疗慢性胆管炎,预防胆道蛔虫是防止结石复发的重要环节。[Objective] To evaluate the effect to diminish inflammation and accelerate choleresis for prevention from post-operation recurrent cholangitis. [Method] A history contrast follow-up study was made between the patients treated with diminishing inflammation and accelerating choleresis （group A： 324 patients, routine therapy plus diminishing inflammation and accelerating choleresis for one to three months after operation） and those with routine therapy （group B： 859 patients）. [Result] A follow-up survey of 236 cases in group A （occupying 72.84%） and 537 cases in group B （62.51%） were obtained by regular visits or correspondence, the post-operation cholangitis recurrent rate was 15.25% （36/236）, re-operation rate was 5.08% （12/236） in group A; but it was 32.8% （176/537） and 16.8% （90/537） respectively in group B. （X^2=25.2846, P 〈0.005; X^2 =19.5101, P 〈0.005）. [Conclusion] The therapy to diminish inflammation and accelerate eholeresis and killing ascafid might take effect to cure the chronic cholangitis and prevention from stone recurrence after operation for hepatolithiasis.

关 键 词：肝胆管结石 胆管炎:疗效 

分 类 号：R657.4[医药卫生—外科学]